AI Drug Discovery Firm Insilico Raises $110M to Fuel Biotech Innovation
Summary
Insilico Medicine, an AI-driven drug discovery company, raised $110 million in Series E funding to propel its AI platform Pharma.AI, advance its drug pipeline, and bolster biopharmaceutical R&D, harnessing biology, clinical data, and generative chemistry for innovative drug development.
Key Points
- Insilico Medicine secured $110 million in an oversubscribed Series E funding round.
- The funds will be used to advance Insilico's drug pipeline, AI platform, and biopharmaceutical research and development.
- Insilico's AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific research, and generative chemistry for drug discovery.